1. Home
  2. SEER vs GANX Comparison

SEER vs GANX Comparison

Compare SEER & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.79

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEER
GANX
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
78.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SEER
GANX
Price
$1.79
$1.78
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
364.2K
507.4K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
9.40
31.46
EPS
N/A
N/A
Revenue
$16,578,000.00
$55,180.00
Revenue This Year
$2.14
N/A
Revenue Next Year
$25.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$1.65
$1.41
52 Week High
$2.41
$4.34

Technical Indicators

Market Signals
Indicator
SEER
GANX
Relative Strength Index (RSI) 45.19 46.62
Support Level $1.76 $1.73
Resistance Level $1.84 $2.09
Average True Range (ATR) 0.07 0.10
MACD -0.01 -0.00
Stochastic Oscillator 32.26 62.50

Price Performance

Historical Comparison
SEER
GANX

About SEER Seer Inc.

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: